RespireRx Pharmaceuticals Inc (CE) (RSPI) 銘柄情報

Their filings have indicated they consider the OTC to be hindering fund raising. They didn't give much effort to maintain OTC status falling to EM.

Logical to believe another approach is possibly in play. Normal companies supposedly in need of cash would at minimum communicate and present company to prospective investment entities, etc. The lack of suggests they have other plans established and in motion.

Yes.

My next sentence implied that no?

"Maybe they just get funding deal and go straight to Nasdaq?? Have seen mergers before with a company with cash looking for development assets"

"I was suggesting merger with already established Nasdaq company with cash looking for assets".

Is that really what you meant by this?
"Maybe they just get funding deal and go straight to Nasdaq??"

What assets? I wasn't unclear. I said that THE SHARES that you hold essentially are not marketable.

LT - Considering Lippa's history, I don't think a merger is in his nature. Besides, if that were the aim, RSPI would not be in EM. Right? It would be interesting to see who is buying while in EM - could it be RSPI in anticipation of an explosion?

Why aren’t these assets marketable?

Do you think DOD and NIH involvement is a joke?

Sorry if confusing but I was suggesting merger with already established Nasdaq company with cash looking for assets.

I suppose with your level of interest here you would like to see that as well. No?

"Maybe they just get funding deal and go straight to Nasdaq??"
Have you read the NASDAQ listing standards? It wouldn't seem so....RSPI doesn't come close to meeting any of them.
https://listingcenter.nasdaq.com/assets/initialguide.pdf

It says a lot that you actually believe that this board has been read 75,000 times in the last 24 hours. But that's a different issue than the one that was being discussed.....the breakout board IS NOT based on reads. Do I need to explain it again?

Your shit ton of due diligence has resulted in your holding of shares that essentially are not marketable.

I hope that comes true. I have been waiting for almost 5 years now.

It makes you wonder...

Are they serious about drug development and changing people's lives or not?

You just can't do the science part (which I think has positioned their candidates well) and completely ignore the business/stakeholder/communication side of the equation....

This is from last July.

Here’s a repost of my email to Dr Milap Sandhu (msandhu@sralab.org) who will manage CX1739’s clinical trial, funded by the DoD:

Hello Dr Sandhu,

I’m reaching out to you about the recent announcement of a DoD funded study of CX1739. Could you confirm that this is being planned, and if so when will recruitment begin?

I appreciate your time,

Bruno


He promptly replied:

Dear Bruno,

Thank you for reaching out.

Yes, we are planning to initiate a study with CX1739 in individuals with SCI. We are at early stages of this research and it'll take a few months before we begin enrollment.

Are you or someone you know has a spinal cord injury?

Best regards,
Milap

"progress behind the scenes isn't halted"

They just need to get filings done which was supposedly well underway until this "pause" to get off this EM.

But the concern is how many opportunities to attract talent resources, collaborative resources, partnerships, position the company for further fair value investment, build out the shareholder base, position to capitalize on clinical success etc, etc is passing them by??

Nah I don't think so as long as progress behind the scenes isn't halted look at Ltnc spent over a year in EM then suddenly remmerged from 001 to 02 cent run and they got 10x OS than ours

Anyone know anything about the eoy shareholders letter that was promised 

Yep it makes the company look real bad and will also hurt other contracts. Really makes no sense at all. Poor management to say the least. The longer this drags on the harder it will be to get off the expert market.

Curious that the transfer agent has not updated the OS since mid-November. It seems in the past this was a weekly occurrence....

That would be management's choice...

Why on earth they brought this company onto this expert market is beyond me. It really looks silly.

Especially in light of a DOD funded phase 2 on one candidate and working with the NIH on preclinicals and likely phase 1 funding for another candidate as well as significant effort and patent positioning related to their OSA program that the company has chunks of funding lined up at 20 mil valuation, which they stated is low!

Executives and institutional stakeholders have significant funds linked to equity positions. Certainly many see the need for liquidity and capitalizing on their position on 3 different platforms before opportunity to attract resources and investment interest passes them by.

I would hope so...

"I would not be surprised to get an update soon on how the setting up of the trial is unfolding, recruiting of subjects, etc."

They originally stated hoping to initiate trial end of last year. I would think starting fresh in 2025 to get the DOD funds rolling on this phase 2 would be important from many angles.

On top of that I believe according to what I could gleen from NIH websites, that they would hear about grant funding for KRM-ll-81 in the next few months. So a material event related to the gabakine program is likely on the horizon.

And on top of that their OSA program licensor UIC has a VA sponsored dronabinol phase 1/2 projected to start Q1. I would like to know how this program fits within the overall plans/FDA guidance of their OSA program.

I would love that but doubtful. My fear is that we stay on the expert market. Been doing the OTCs a long time and so many end up being pieces of crap. Meanwhile we just hold our shares.

More press mentions RespireRx Pharmaceuticals, in particular the relevance to spinal cord neuroplasticity, which is, by the way the reason why Dr. Dariusz Nasiek joined the board of director, and provided 100000$ in cash, which he arranged to be backed by 33 million shares of RSPI as a disincentive to further dilution.

And in addition, we should bear in mind that the DoD clinical trial funding is specifically about using the new ampakine CX1739 to support therapeutic hypoxia for recovery of spinal cord damage.

So the pieces of the puzzle are coming together. I would not be surprised to get an update soon on how the setting up of the trial is unfolding, recruiting of subjects, etc.

I posted here earlier this year the name of the Dr who will run the trial, and where. I also confirmed with him that this was indeed underway. Let me try to get in touch with him again.

https://www.einnews.com/pr_news/773474888/spinal-cord-injury-therapeutics-market-projected-to-witness-substantial-growth-2024-2031-abbvie-inc-pfizer-inc

https://southeast.newschannelnebraska.com/story/52104007/spinal-cord-injury-therapeutics-market-projected-to-witness-substantial-growth-2024-2031-abbvie-inc-pfizer-inc

Maybe they just get funding deal and go straight to Nasdaq?? Have seen mergers before with a company with cash looking for development assets. Could this be the reason for the non chalant approach the past 6 months??

I mean they think the OSA program is worth 20-40 million. The phase 2 candidate is worth a chunk certainly and KRM-ll-81 with a robust set of successful preclinicals might be more valuable than all the rest combined…

Many think this is worth a nickel or two now in anticipation of multiple clinical trials forthcoming..

So when it shows 75000 reads in a day that is coming from 3 of us permabulls who do a shit ton of due diligence and expecting company executives to meet their fiduciary duties?

And this is similar daily for months on end…. Uh huh.

I agree and they need to get this resolved asap!

Position on the BOB is based on "the change in posting activity in the past 24 hours vs. the average from the prior 7 days", not the number of board reads.
On a board like this just a few posters can have a big influence on a BOB position. For example you and 2 other posters account for more than half of the most recent poster activity, making up the majority of what you refer to as "so much interest in this EM stock".

I think it is board reads…

But why so much interest in this EM stock?

Continually..

Tell him all of it. The Break out board measures posting activity and has zero to do with the Company's operations.

Sadly the more time that goes by they will never get currant. Still makes no sense they didn't file.

Break out board

Bob? What's that? 

Imagine what it will be like if they ever go current again?

Then through in an FDA Approval and or institutional partnerships we could all be celebrating here.

Look at that, RSPI in back on the BoB, not bad for a ticker in the EM!

Some people like the paint color green, some like the paint color red.

I doubt there is any or will be any effort to revive older ampakine compounds. They have already focused soley on the low impact ampakines and have this phase 2 for SCI funded and supposedly I think a presentation a few years back suggested they needed just funding to get CX-1739 or CX717 in ADHD phase 2 clinicals. I am guessing there is way too much risk and stigma with the old high impact compounds. Plus they have an enormously promising gabakine and an OSA program with patent position that both are and can be extremely valuable. Focus and updates need to be centered around these compounds heading into clinicals.

Now maybe in the future they can afford to explore the past with newer technology, but given the current lack of everything seems far fetched to even place into ones imagination...

Why would anyone sell RSPI stock while it is in EM status to profit such small amount of money?

LT - CX9292, a high impact ampakine with short half-life, was shown it can be administered orally by drinking water and was shown to be effective in mice. Are there others? Am I being biased in my holy grail assessment of RSPI impact on neuropharmacology? Lippa also is (was?) head of venture capital firms - is there financing that we don't know about? Is RSPI quietly accumulating their stock at ridiculous prices? Then there is that PhD thesis online where the author complained that he could not publish his results on CX929 until 2026 (the thesis is no longer available). Does that mean for the university researchers have to sign nondisclosures to gain access to the ampakines for research? They only can publish when given permission? So many questions - will January finally give us the answers?

Maybe, but I don't see RSPI having any involvement. They can't even get the basic business entity activities accomplished and have zero bandwidth to attempt to create targeting ampa compounds as they have enough on their plate now that doesnt appear to be moving. Their ampakine focus for the next how many years can only be on the low impact compounds with the DOD phase 2 SCI trial and how that may lead into ADHD trials. Let alone needing to dedicate resources to the OSA and gabakine programs which may be much more valuable with larger market reach anyhow.

Possibly nanoparticles can revive past high-impact ampakines, but I am guessing that ship has long sailed here with no patent rights any further on those long lost compounds. Now maybe.... if they acted like a legit mid major pharma and sustained valuations representitive of their progress into clinical trials on 3 seperate platforms they could then have the flexibility to acquire the people resources, the collaborative resources and smallish funding necessary to pursue an ampakine revival and expansion of that platform.... But as the months tick by, they appear to have zero desire in this regards.

I see your points, and the possibility if new technology can mitigate past ampakine concerns and revive development, but do you think the company sees any of it or has any desire to go down those paths?

Market research report from Coherent Market Insights mentions RespireRx:

Spinal Cord Injury Therapeutics Market Projected To Witness Substantial Growth, 2024-2031:

Key Players Covered In This Report:

Teva Pharmaceutical Industries Ltd.
AbbVie Inc
Pfizer Inc.
Reddy's Laboratories Ltd
Zydus Cadila
ReNetX Bio, Inc
InVivo Therapeutics Holdings
Lineage Cell Therapeutics, Inc
Kringle Pharma Inc.
Acorda Therapeutics Inc.
Bioaxone Biosciences, Inc
RespireRx Pharmaceuticals Inc.
NervGen
Rising Pharmaceuticals, Inc
ScieGen Pharmaceuticals, Inc
MSN Laboratories Private Limited
Lannett Co Inc.


https://menafn.com/1109048318/Spinal-Cord-Injury-Therapeutics-Market-Projected-To-Witness-Substantial-Growth-2024-2031-Abbvie-Inc-Pfizer-Inc

Another indication for ampakine research?

Small-molecule targeting AMPA-mediated excitotoxicity has therapeutic effects in mouse models for multiple sclerosis

Dongxu Zhai, Shuxin Yan, James Samsom, Le Wang, Ping Su, Anlong Jiang, Haorui Zhang, Zhengping Jia Izhar Wallach, Abraham Heifets, Chiara Zanato, Chih-Chung Tseng, Albert H C Wong, Iain R Greig, Fang Liu
Affiliations Expand
PMID: 38064562 PMCID: PMC10708182 DOI: 10.1126/sciadv.adj6187
Sci Adv. 2023 Dec 8;9(49):eadj6187.
Epub 2023 Dec 8.
Abstract
While most research and treatments for multiple sclerosis (MS) focus on autoimmune reactions causing demyelination, it is possible that neurodegeneration precedes the autoimmune response. Hence, glutamate receptor antagonists preventing excitotoxicity showed promise in MS animal models, though blocking glutamate signaling prevents critical neuronal functions. This study reports the discovery of a small molecule that prevents AMPA-mediated excitotoxicity by targeting an allosteric binding site. A machine learning approach was used to screen for small molecules targeting the AMPA receptor GluA2 subunit. The lead candidate has potent effects in restoring neurological function and myelination while reducing the immune response in experimental autoimmune encephalitis and cuprizone MS mouse models without affecting basal neurotransmission or learning and memory. These findings facilitate development of a treatment for MS with a different mechanism of action than current immune modulatory drugs and avoids important off-target effects of glutamate receptor antagonists. This class of MS therapeutics could be useful as an alternative or complementary treatment to existing therapies.

Yeah, versus a grotesquely deflated valuation that costs added debt, dilution and stagnates opportunities, limits flexibility, etc.

Brilliant strategy.

What do they think fair valuation is? Surely more than the independent valuation of the OSA program considering the gabakine has the premier look exiting preclinicals and DOD funding the other platform.

They are weary of the market getting too excited, and creating grotesquely inflated hype. They seek a path to steady sustainable appreciation of the share price.

You would think listing correct management and BOD would be important!

And all 3 platforms have way outdated information!

It is illogical to cry about lack of funding and otc liquidity when you present the company like a 6th grade science project..

Yet executives, BOD, institutional have all lined up behind equity positions here last few years!! What does that tell you coupled with the lack of desire to parlay a significant DOD funded phase 2 into investor interest!!

I agree that the current state of the website is quite awful. Not only does it look amateurish, on the company management page it lists Dr. James Manuso as the CEO. He left the company on September 30, 2018.

https://www.respirerx.com/corporate/management.html

https://www.globenewswire.com/news-release/2018/06/19/1526825/0/en/RespireRx-Pharmaceuticals-Inc-Announces-Resignation-of-Dr-James-S-Manuso.html

Why did someone sell at this level to drop the pps?

That would be a start! They need an updated website to clearly highlight the asset platforms, current progress, market potential, expected milestones, etc.

An obviously they need off this EM market to bring liquidity and interest back that is essential to capitalize on opportunities to gain talent resources, collaborations and position the assets for next steps so if BP joins the picture they can maximize their position.

bottomline convey a strategy and execute it. fiduciary duty should be a proud endeavor not whatever the current status has been

Great job he needs to know we are gonna hold him to his word!

Just wrote Jeff asking if anything new that could be reported and if he was still working on shareholders news letter. We will see what happens

I recall some poster stating the company chose to "pause" the entire filing process after beginning it and getting most of the way done I think was suggested.

Maybe the company saw further progress on KRM-ll-81 was going to wait for NIH grant status in Q1 2025 and the DOD funded SCI phase 2 was likely to be pushed into 2025 as well versus EOY 2024. IF the OSA program is stalled awaiting results of this phase 1/phase 2 clinical UIC is conducting that may indicate a change of approach with OSA and hence the year long silence on that program. Silence on the EM may have been advantageous in some regard.

The ingredients are there and setting up for a very active and special 2025 as they are on the cusp of clinical trials on all 3 platforms. I hope they get some leadership help as there is no reason these assets should be valued as such. Even at a nickel and 50 million valuation seems really cheap having 3 platforms heading to clinicals where the preclincal efforts have been substaintial and successful to improve odds of success in clincals. I'm optimistic a new year will be transformative from all angles. GLTA.

"AI overview" via Google... Interesting, but could find no articles...AI overreach? But if not could be really huge!

Ampakines are drug candidates that may be useful in treating multiple sclerosis (MS) because they can modulate AMPA-type glutamate receptors (AMPARs):
AMPARs and MS
Glutamate excitotoxicity, mediated by AMPARs, can damage neurons and oligodendrocytes, which are cells that produce myelin in the central nervous system (CNS). In MS, activated immune cells release large amounts of glutamate, which can contribute to lesions.
Ampakines and AMPARs
Ampakines are positive allosteric modulators of AMPARs. They can increase cytosolic calcium levels in astrocytes, which may be sensitive to modulation by ampakines.
Ampakines as a treatment
Small-molecule antagonists of AMPA-mediated excitotoxicity may be a promising treatment for MS. These antagonists could be an alternative or complementary treatment to current immune modulatory drugs.
Glutamate homeostasis
Glutamatergic homeostasis is important for normal physiological processes. Treatment strategies that regulate glutamate homeostasis may benefit MS patients